Anesthesia · Neuromuscular BlockerRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Succinylcholine Chloride ANDA217873

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 12:32:32 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on pricing and market share for existing neuromuscular blockers. The strongest clinical anchor is Perturbation Based Balance Training Versus Progressive Neuromuscular Training as an Adjunct to Conventional Physiotherapy for Pain Reduction and Functional Improvement in Knee Osteoarthritis (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 1 regulatory and 1 competitive items passed relevance filtering for STERISCIENCE.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369) (Humanexa Signals) — sponsor/company relevance (pfizer). This approval allows STERISCIENCE to enter the market for Succinylcholine Chloride, potentially increasing competition among neuromuscular blockers.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL) (FDA). Entity match (steriscience); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

Key Opportunities

The entry of a generic competitor may pressure pricing strategies and could lead to a decrease in revenue for established brands in the neuromuscular blockers segment.
Portfolio teams should assess the impact of this new entrant on pricing and market share for existing neuromuscular blockers.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies of STERISCIENCE following this approval.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)
FDAmedium relevance
Entity match (steriscience); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VALACYCLOVIR HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Perturbation Based Balance Training Versus Progressive Neuromuscular Training as an Adjunct to Conventional Physiotherapy for Pain Reduction and Functional Improvement in Knee Osteoarthritis
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Mercklow relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Acute beetroot juice ingestion fails to improve sprint performance and neuromuscular function in trained male sprinters: a randomized, double-blind, placebo-controlled study.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

STERISCIENCE
Succinylcholine Chloride

Commercial impact

medium

The entry of a generic competitor may pressure pricing strategies and could lead to a decrease in revenue for established brands in the neuromuscular blockers segment.

Regulatory impact

low

The approval status indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

What to watch

Monitor market entry timelines and pricing strategies of STERISCIENCE following this approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.